A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
1 other identifier
interventional
285
1 country
104
Brief Summary
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 hypertension
Started Mar 2023
104 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 24, 2023
CompletedStudy Start
First participant enrolled
March 13, 2023
CompletedFirst Posted
Study publicly available on registry
March 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 15, 2025
CompletedJanuary 20, 2026
January 1, 2026
1.8 years
February 24, 2023
January 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)
Baseline (Randomization) to Week 12
Secondary Outcomes (11)
Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
Baseline to Week 4
Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
at Week 4
Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
Baseline to Week 4
Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)
Baseline to Week 12
Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
Baseline to Week 4
- +6 more secondary outcomes
Study Arms (3)
Placebo
PLACEBO COMPARATORPlacebo once daily for 12 weeks
Dose 1
EXPERIMENTALlorundrostat Dose 1 once daily for 12 weeks
Dose 2
EXPERIMENTALlorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks
Interventions
lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
Eligibility Criteria
You may qualify if:
- At least 18 years of age at the time of signing the informed consent form
- At Screening: AOBP SBP of 140-180 mmHg and AOBP DBP of 65-110 mmHg, or AOBP DBP of 90-110 mmHg
- hour average ABPM SBP of 130-180 mmHg or 24-hour average ABPM DBP \>80 mmHg
- Taking between 2 and 5 AHT medications, inclusive, at Screening visit.
- BMI of 18-40 kg/m2 inclusive at Screening
You may not qualify if:
- eGFR \<45 mL/min/1.73 m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
- Serum potassium \>5.0 mmol/L at Screening or \>4.8 mmol/L at Randomization
- Serum sodium \<135 mmol/L at Screening
- History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to Screening.
- Diabetes mellitus with a glycosylated hemoglobin (HbA1c) \>9% (\>74.9 mmol/mol) at Screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (104)
Cardiology, P.C. - Birmingham
Birmingham, Alabama, 35211, United States
University of Alabama at Birmingham (UAB) - Vascular Biology and Hypertension Program
Birmingham, Alabama, 35294, United States
Chandler Clinical Trials
Chandler, Arizona, 85224, United States
Brown Road Family Medicine
Mesa, Arizona, 85213, United States
Scottsdale Clinical Trials (Elite Clinical Network)
Scottsdale, Arizona, 85260, United States
Fiel Family & Sports Medicine
Tempe, Arizona, 85383, United States
Noble Clinical Research
Tucson, Arizona, 85704, United States
Del Sol Research Management, LLC
Tucson, Arizona, 85715, United States
The Medical Research Group Inc.
Fresno, California, 93720, United States
Marvel Clinical Research
Huntington Beach, California, 92647, United States
University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California, 92037, United States
Clinical Trials Research
Lincoln, California, 95648, United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Catalina Research Institute
Montclair, California, 91763, United States
Northridge Clinical Trials
Northridge, California, 91325, United States
University of California Irvine Medical Center
Orange, California, 92868, United States
Triwest Research Associates
San Diego, California, 92108, United States
San Jose Clinical Trials
San Jose, California, 95117, United States
Blue Coast Research Center
Vista, California, 92081, United States
Accelerated Enrollment Solutions (AES)- Vista
Vista, California, 92083, United States
Delta Waves, Inc.
Colorado Springs, Colorado, 80918, United States
CMR of Greater New Haven
Hamden, Connecticut, 06517, United States
Indago Research & Health Center, Inc.
Hialeah, Florida, 33012, United States
Clinical Neuroscience Solutions, Inc (Jacksonville)
Jacksonville, Florida, 32256, United States
Reserka, LLC
Miami, Florida, 33176, United States
Nuovida Research Center Corp
Miami, Florida, 33186, United States
Clinical Neuroscience Solutions, INC.
Orlando, Florida, 32801, United States
Patron Medical - Andres Patron D.O. (Patron Ventures, LLC)
Pembroke, Florida, 33026, United States
Progressive Medical Research
Port Orange, Florida, 32127, United States
Clinical Research of West Florida, Inc.
Tampa, Florida, 33606, United States
The Pierone Research Institute (Elligo Health Research)
Vero Beach, Florida, 32960, United States
Nephrology Associates, PC - Downtown Augusta
Augusta, Georgia, 30901, United States
Accel Research Sites
Decatur, Georgia, 30030, United States
Georgia Clinical Research, LLC
Lawrenceville, Georgia, 30044, United States
Randomize Now
Peachtree City, Georgia, 30269, United States
Alta Pharmaceutical Research Center
Peachtree Corners, Georgia, 30092, United States
Fellows Research Alliance, Inc
Savannah, Georgia, 31406, United States
Eagle Clinical Research
Chicago, Illinois, 60621, United States
The University of Chicago Medicine
Chicago, Illinois, 60637, United States
GenHarp Clinical Solutions
Evergreen Park, Illinois, 60805, United States
Southern Illinois School of Medicine
Springfield, Illinois, 62702, United States
Franciscan Physician Network-Indiana Heart Physicians
Indianapolis, Indiana, 46237, United States
Indiana Clinical Research
Merrillville, Indiana, 46410, United States
The Research Group of Lexington, LLC
Lexington, Kentucky, 40503, United States
Advanced Internal Medicine, PLLC (Elligo Health Research)
Paducah, Kentucky, 42001, United States
Versailles Family Medicine
Versailles, Kentucky, 40383, United States
Cambridge Clinical Trials
Alexandria, Louisiana, 71301, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Boston Clinical Trials
Boston, Massachusetts, 02131, United States
ActivMed Practices & Research, LLC
Methuen, Massachusetts, 01844, United States
Saint Louis University
St Louis, Missouri, 63104, United States
Quality Clinical Research Inc. (QCR) - Omaha
Omaha, Nebraska, 68114, United States
Henderson Clinical Trials
Henderson, Nevada, 89052, United States
Las Vegas Clinical Trials
Las Vegas, Nevada, 89030, United States
Oasis Clinical Trials
Las Vegas, Nevada, 89121, United States
Renown Regional Medical Center
Reno, Nevada, 89502, United States
Seacoast Kidney & Hypertension Specialist
Portsmouth, New Hampshire, 03801, United States
Albany Medical College Div of Community Endocrinology
Albany, New York, 12203, United States
University of Buffalo
Buffalo, New York, 14215, United States
Columbia University
New York, New York, 10032, United States
Marian David, MD, PC (Elligo Health Research)
New York, New York, 11415, United States
Triad Internal Medicine
Asheboro, North Carolina, 27205, United States
Asheville Clinical Trials (Elite Clinical Network)
Asheville, North Carolina, 28803, United States
Duke University Medical Center Heart Center Clinical Research Unit
Durham, North Carolina, 27710, United States
East Carolina University (ECU) Physicians - East Carolina Heart Institute - East Carolina University Location
Greenville, North Carolina, 27834, United States
Lucas Research, Inc.
New Bern, North Carolina, 28557, United States
Iredell Memorial Hospital, Inc (Elligo Health Research)
Statesville, North Carolina, 28677, United States
Lillestol Research LLC
Fargo, North Dakota, 58104, United States
Research Innovations (Elligo Health Research)
Beavercreek, Ohio, 45431, United States
Diabetes and Endocrinology Associates of Stark County, Inc.
Canton, Ohio, 44718, United States
Intrepid Research
Cincinnati, Ohio, 45245, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Centricity Research (Aventiv Research) - Women's Health
Dublin, Ohio, 43016, United States
STAT Research
Springboro, Ohio, 45066, United States
Williamette Valley Clincial Studies
Eugene, Oregon, 97404, United States
AMS Cardiology
Horsham, Pennsylvania, 19044, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Accelerated Enrollment Solutions (AES)- Anderson
Anderson, South Carolina, 29621, United States
WR- Notus Clinical Trials, LLC
Charleston, South Carolina, 29414, United States
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
Chattanooga Medical Research
Chattanooga, Tennessee, 37404, United States
Lifedoc Research
Memphis, Tennessee, 38115, United States
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee, 38119, United States
Vanderbilt University Medical Center (VUMC)
Nashville, Tennessee, 37232, United States
Elligo Health Research
Austin, Texas, 78704, United States
Punzi Medical Center
Carrollton, Texas, 75006, United States
David Turbay, MD, PLLC (Elligo Health Research)
El Paso, Texas, 79905, United States
Houston Methodist Research Institute
Houston, Texas, 77030, United States
Juno Research LLC
Houston, Texas, 77040, United States
Gulf Coast Clinical Research
Houston, Texas, 77070, United States
Medical Colleagues of Texas, LLP (Elligo Health Research)
Katy, Texas, 77450, United States
Synergy Groups Medical - Bissonet Site
Katy, Texas, 77494, United States
PRX Research - Mesquite
Mesquite, Texas, 75149, United States
Medical Colleagues of Texas, LLP (Elligo Health Research)
Paris, Texas, 75462, United States
ACRC Trials
Plano, Texas, 75024, United States
Clinical Investigations of Texas (CIT)
Plano, Texas, 75075, United States
Sun Research Institute (SRI) - San Antonio
San Antonio, Texas, 78215, United States
San Antonio Clinical Trials
San Antonio, Texas, 78240, United States
Sugar Lakes Family Practice (Elligo Health Research)
Sugar Land, Texas, 77479, United States
The University of Utah
Salt Lake City, Utah, 84108, United States
Burke Internal Medicine
Burke, Virginia, 22015, United States
Charlottesville Medical Research
Charlottesville, Virginia, 22911, United States
Eastern Virginia Medical School
Norfolk, Virginia, 23510, United States
Centricity Research (IACT Health) (Hampton Roads Center For Clinical Research, Inc.)) - Suffolk Multispecialty Research
Suffolk, Virginia, 23435, United States
Related Publications (1)
Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, Weir MR, Ofili EO, Mehra R, Luther JM, Cohen DL, Sarraju A, Wilkinson MJ, Flack JM, Rodman D, Nissen SE; Advance-HTN Investigators. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025 May 8;392(18):1813-1823. doi: 10.1056/NEJMoa2501440. Epub 2025 Apr 23.
PMID: 40267417DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 24, 2023
First Posted
March 15, 2023
Study Start
March 13, 2023
Primary Completion
January 15, 2025
Study Completion
January 15, 2025
Last Updated
January 20, 2026
Record last verified: 2026-01